A clinical trial is being conducted by the pharma company AstraZeneca and Saint Luke’s Mid America Heart Institute in Kansas City in which hospitalized COVID-19 patients are given the diabetes drug Farxiga. The blood-sugar-lowering effects of the drug cannot combat the coronavirus itself, but researchers are looking for signs it may reduce the risk of some of the dangerous complications of the coronavirus. Read more